Objectives: Neonatal hypoxia ischemia (HI) is an injury that can lead to neurological impairments such as behavioral and learning disabilities. Granulocyte-colony stimulating factor (G-CSF) has been demonstrated to be neuroprotective in ischemic stroke however it has also been shown to induce neutrophilia, ultimately exacerbating neuronal injury. Our hypothesis is that coadministration of anti-neutrophil antibody (Ab) with G-CSF will decrease blood neutrophil counts thereby reducing infarct volume and improving neurological function post HI brain injury. Methods: Rat pups were subjected to unilateral carotid artery ligation followed by 2.5 h of hypoxia. Animals were randomly assigned to five groups: Sham (n = 15), vehicle (HI, n = 15), HI with G-CSF treatment (n = 15), HI with G-CSF + Ab treatment (n = 15), and HI with Ab treatment (n = 15). Ab (325 μg/kg) was administered intraperitoneally while G-CSF (50 μg/kg) was administered subcutaneously 1 h post HI followed by daily injections for 3 consecutive days. Animals were euthanized at 96 h post HI for blood neutrophil counts and brain infarct volume measurements as well as at 5 weeks for neurological function testing and brain weight measurements. Lung and spleen weights at both time points were further analyzed. Results: The G-CSF treatment group showed tendencies to reduce infarct volume and improve neurological function while significantly increasing neutrophil counts. On the other hand, the G-CSF + Ab group significantly reduced infarct volume, improved neurological function and decreased neutrophil counts. The Ab alone group showed reversal of the neuroprotective effects of the G-CSF + Ab group. No significant differences were found in peripheral organ weights between groups. Conclusion: Our data suggest that coadministration of G-CSF with Ab not only prevented brain atrophy but also significantly improved neurological function by decreasing blood neutrophil counts. Hence the neuroprotective effects of G-CSF may be further enhanced if neutrophilia is avoided.
Introduction
Hypoxia ischemia (HI) refers to the insufficient blood and oxygen supply to the brain that results in severe brain damage and the development of neurological impairments such as cerebral palsy; cognitive, behavioral, socialization and learning difficulties; and seizures and encephalopathy. It is the main cause of mortality and morbidity in infants; affecting two to four of 1000 full-term births and nearly 60% of premature births (Bracewell and Marlow, 2002; Ferriero, 2004; Vannucci and Vannucci, 1997; Volpe, 2001) . Current clinical treatments available such as anticonvulsants, therapeutic hypothermia, and fluid and electrolyte management, have proven only some degree of success (Koenigsberger, 2000; Zanelli et al., 2009) , thus the necessity for alternative strategies to either replace or amplify the current therapeutic protocols.
Granulocyte-colony stimulating factor (G-CSF), a 20-kDa hematopoietic growth factor, stimulates survival, proliferation and development of neuronal stem cells and regulates maturation and survival of neutrophil granulocyte precursors (Roberts, 2005; Schneider et al., 2005; van Raam et al., 2008) . G-CSF has anti-apoptotic (Komine-Kobayashi et al., 2006; Schabitz et al., 2003; Schneider et al., 2005) and anti-inflammatory (Gibson et al., 2005) effects and has been shown to confer neuroprotection in a number of in vivo studies (Popa-Wagner et al., 2010; Solaroglu et al., 2006 Solaroglu et al., , 2009 Yata et al., 2007) . Rats treated with G-CSF tend to have Neurobiology of Disease 69 (2014) 192-199 
